{
    "clinical_study": {
        "@rank": "146237", 
        "arm_group": [
            {
                "arm_group_label": "CJM112", 
                "arm_group_type": "Experimental", 
                "description": "CJM112 in different doses; single ascending and multiple ascending"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Secukinumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Active investigational drug."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, double-blind, placebo and positive controlled, single and multiple dose\n      escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics\n      of CJM112 in chronic plaque-type psoriasis patients."
        }, 
        "brief_title": "Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Plaque-type Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women 18-65 years of age at time of consent\n\n          -  Chronic plaque-type psoriasis diagnosed for at least 6 months at time of\n             randomization\n\n          -  At randomization, moderate to severe psoriasis as defined by:\n\n          -  PASI score of 12 or greater and,\n\n          -  IGA score of 3 or greater and,\n\n          -  Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.\n\n          -  Female patients may be included according to the following:\n\n        Women of child-bearing potential, defined as all women physiologically capable of becoming\n        pregnant, using highly effective methods of contraception during dosing and for 5 times\n        the terminal half-life of study treatment.\n\n        \u2022 Male subjects must agree to comply with two highly effective contraceptive methods\n\n        Exclusion Criteria:\n\n          -  Forms of psoriasis other than chronic plaque-type (incl. drug induced psoriasis)\n\n          -  Ongoing use of prohibited psoriasis treatments  and other prohibited medication at\n             randomization. Washout periods detailed in the protocol have to be adhered to\n\n          -  Previous treatment with IL-17 or IL17R blocking agents, including secukinumab\n\n          -  Any live vaccines (including nasal-spray flu vaccine) starting from 6 weeks before\n             screening, during the study, and up to 24 weeks after the last dose of CJM112 or\n             secukinumab\n\n          -  Evidence of active tuberculosis at screening\n\n          -  Active systemic infections (other than common cold)\n\n          -  Pregnant or nursing (lactating) women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828086", 
            "org_study_id": "CCJM112X2101"
        }, 
        "intervention": [
            {
                "arm_group_label": "CJM112", 
                "description": "Monoclonal antibody", 
                "intervention_name": "CJM112", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Secukinumab", 
                "description": "Monoclonal antibody", 
                "intervention_name": "Secukinumab", 
                "intervention_type": "Biological", 
                "other_name": "AIN475"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Liquid for subcutaneous injection without active drug.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Psoriasis, chronic plaque-type psoriasis, IL17, monoclonal antibody", 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72201"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Hollywood", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91605"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aventura", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33180"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33714"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Normal", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61761"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66211"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14623"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinatti", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73112"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety as assessed by the number of participants with adverse events as measured by laboratory parameters, vital signs, electrocardiogram and the collection of serious and non-serious adverse events.", 
            "measure": "Number of participants with adverse events as a measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "19 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828086"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Psoriasis Area and Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "19 weeks"
            }, 
            {
                "description": "Measurement of drug levels in the blood of treated patients.", 
                "measure": "Total CJM112 Concentrations in Serum", 
                "safety_issue": "No", 
                "time_frame": "19 weeks"
            }, 
            {
                "description": "Assessment of the ability of the compound to evoke an immune response. Assessed in blood of treated patients.", 
                "measure": "Concentration of anti-CJM112 Antibodies in Serum", 
                "safety_issue": "Yes", 
                "time_frame": "19 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}